

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 June 2019 (20.06.2019)



(10) International Publication Number
WO 2019/115684 A1

(51) International Patent Classification:

A61K 51/04 (2006.01) A61K 103/40 (2006.01)
A61P 35/04 (2006.01) A61K 103/00 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2018/084738

(22) International Filing Date:

13 December 2018 (13.12.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

17206887.6 13 December 2017 (13.12.2017) EP

(71) Applicant: SCIENCONS AS [NO/NO]; Gullhaugveien 7,
NO-0484 Oslo (NO).

(72) Inventor: LARSEN, Roy Hartvig; Lunden 20, N-0598
Oslo (NO).

(74) Agent: AERA A/S; Gammel Kongevej 60, 18th floor,
DK-1850 Frederiksberg C (DK).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPLEX COMPRISING A PSMA-TARGETING COMPOUND LINKED TO A LEAD OR THORIUM RADIONUCLIDE




Figure 1

(57) Abstract: The present invention relates to complexes comprising a prostate- specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as ^{212}Pb or ^{227}Th , through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*